MEASURING ADHERENCE TO, AND PERSISTENCE WITH, ADVANCED THERAPY IN PATIENTS WITH LUPUS NEPHRITIS IN THE REAL-WORLD SETTING (ISPOR 2026) - Mar 6, 2026 - Abstract #PCR197; Pres time: May 20, 2026; 09:00 AM - 11:30 AM; "Here we measure real-world adherence to, and persistence with, advanced therapies (belimumab and voclosporin) in patients with LN. The IQVIA PharMetrics Plus closed claims database was used to identify adult US patients diagnosed with LN between January 2021 and December 2023. In this real-world study, overall adherence to, and persistence with, advanced therapies in patients with LN was poor."
Adherence • Clinical • Metastases • Real-world • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Jesse Sussell, PhD; Anisha M. Patel, PhD; Achal Patel, PhD; Robert Schuldt, PhD; William F. Pendergraft, III, MD, PhD
|